In Q3 of fiscal 2026, the quarter ended Jul 31, 2026, enGene Therapeutics Inc. used $18.9 million of cash from operations, up 26.1% from the same quarter a year earlier. It spent $0 on capital expenditures. Free cash flow was negative, at -$18.9 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jul 31, 2026
|
Q3 FY2026
Jul 31, 2026
|
Q2 FY2026
Apr 30, 2026
|
Q1 FY2026
Jan 31, 2026
|
Q4 FY2025
Oct 31, 2025
|
Q3 FY2025
Jul 31, 2025
|
Q2 FY2025
Apr 30, 2025
|
Q1 FY2025
Jan 31, 2025
|
Q4 FY2024
Oct 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
1
+75.0%
|
0
+0.0%
|
0
+100.0%
|
0
+85.3%
|
0
+100.0%
|
0
+0.0%
|
0
+0.0%
|
0
+27.5%
|
0
|
| Stock-based compensation |
17
+99.7%
|
8
+202.6%
|
4
+56.4%
|
3
+54.9%
|
3
+57.4%
|
3
+76.8%
|
3
+38.2%
|
2
+521.6%
|
2
|
| Operating cash flow |
-103
-10.1%
|
-19
+26.1%
|
-30
-32.9%
|
-29
-12.5%
|
-25
-27.6%
|
-26
-257.0%
|
-23
-62.0%
|
-26
-248.7%
|
-20
|
| Investing | |||||||||
| Capital expenditures |
1
-46.5%
|
0
-100.0%
|
0
+117.8%
|
0
-48.8%
|
0
+83.6%
|
1
+35100.0%
|
0
-74.9%
|
0
-40.9%
|
0
|
| Investing cash flow |
-32
+83.2%
|
30
+2084.3%
|
24
+31.7%
|
-126
-48.6%
|
40
+132.3%
|
1
+69050.0%
|
18
+10126.3%
|
-85
-16691.3%
|
-125
|
| Financing | |||||||||
| Financing cash flow |
144
+140.8%
|
0
+103.4%
|
0
-62.8%
|
142
+14165900.0%
|
2
-96.7%
|
-1
-1407.8%
|
0
-99.9%
|
0
-100.0%
|
60
|
| Change in cash | |||||||||
| Effect of exchange rate |
0
+0.0%
|
0
|
0
|
0
+0.0%
|
0
|
0
|
0
|
0
+0.0%
|
0
|
| Net change in cash |
8
+103.7%
|
11
+144.9%
|
-7
-41.3%
|
-14
+87.8%
|
18
+120.7%
|
-25
-249.4%
|
-5
-102.7%
|
-111
-2782.6%
|
-85
|
| Free cash flow |
-104
-9.3%
|
-19
+28.1%
|
-31
-33.1%
|
-29
-11.8%
|
-25
-28.2%
|
-26
-266.7%
|
-23
-60.3%
|
-26
-230.1%
|
-20
|
| Per share | |||||||||
| Free cash flow per share |
-1.61
+16.3%
|
-0.27
+47.3%
|
-0.44
+2.6%
|
-0.43
+15.3%
|
-0.49
-10.7%
|
-0.52
-217.0%
|
-0.45
-23.9%
|
-0.51
-50.2%
|
-0.45
|
| Dividend per share |
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.